South Africa has become one of the first countries in the world to offer a new HIV prevention injection that works for six months per dose. The drug, lenacapavir, was launched in the town of Secunda in Mpumalanga province, marking a shift from policy discussions to actual injections in public health clinics.
A shot that lasts two seasons
Lenacapavir is a long-acting injectable form of pre-exposure prophylaxis, or PrEP. Unlike daily pills, this injection is given only twice a year. The World Health Organization praised the rollout, calling it a major milestone in South Africa's long fight against HIV. The country has one of the highest HIV burdens in the world, and health officials hope the new option will make prevention easier for people who struggle to take a daily pill.
From government approval to clinic delivery
The launch involved multiple steps. South Africa updated its essential medicines list to include lenacapavir, secured early supply of the drug, and prepared its health systems to deliver the injections. President Cyril Ramaphosa's government led the effort, working with WHO and local partners. WHO Director-General Dr Tedros Adhanom Ghebreyesus delivered a video address for the launch, congratulating the country on moving from policy to implementation ahead of many others.
Why local communities took notice
For people in Secunda and across Mpumalanga, the rollout means a new option for staying HIV-negative without remembering a daily pill. South Africa has long been a global leader in HIV response, driven by strong political commitment and community partnerships. Local health workers see the injection as a practical tool for young women and men who face barriers to consistent prevention. The country joins other early adopter nations seeking to accelerate progress toward ending HIV by 2030.
A step toward ending an epidemic
WHO's Dr Tereza Kasaeva said the rollout demonstrates South Africa's continued commitment to expanding access to innovative HIV prevention tools. The organization remains committed to supporting the country's efforts. While no single tool will end HIV, lenacapavir adds a powerful option to the prevention toolkit. South Africa's move from policy to practice shows what is possible when governments, communities, and partners work together with clear purpose.
